Ad
related to: Moderna
Search results
Should You Buy This Stock After a Regulatory Setback?
The Motley Fool via AOL· 5 days agoThe past two-and-a-half years have been rough for Moderna (NASDAQ: MRNA). Though the biotech was...
US poised to invest millions in mRNA bird flu vaccine amid H5N1 scare
The Telegraph via Yahoo News· 11 hours agoThe US government is poised to announce a multimillion-dollar investment in mRNA vaccines for H5N1...
Moderna Could Pull Back Even More as Traders Nail Down Profits
TheStreet.com· 2 days agoModerna Could Pull Back Even More as Traders Nail Down Profits
Moderna's Options Frenzy: What You Need to Know - Moderna (NASDAQ:MRNA)
Benzinga· 2 days agoLoading... Loading... Deep-pocketed investors have adopted a bullish approach towards Moderna MRNA , and it's something market players shouldn't ignore. Our tracking of public ...
Thousands of cancer patients to trial personalised vaccines
BBC via Yahoo News· 2 hours agoLast month, a patient in London received a personalised mRNA vaccine against melanoma, the deadliest...
The Zacks Analyst Blog Highlights NVIDIA, Constellation Energy, Micron Technology, Moderna and...
Zacks· 21 hours ago(CEG Quick QuoteCEG - Free Report) , Micron Technology (MU Quick QuoteMU - Free Report) , Moderna Inc. (MRNA Quick QuoteMRNA - Free Report) and Qualcomm Inc. (QCOM Quick QuoteQCOM ...
Moderna director Afeyan sells over $2.3 million in company stock By Investing.com
Investing.com· 6 days agoModerna , Inc. (NASDAQ:MRNA) director Noubar Afeyan has sold a portion of his holdings in the...
Why Vaccine Stocks Rallied This Week
Motley Fool via Yahoo Finance· 7 days agoShares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and...
Moderna Shares Had a Bad Day
Barrons.com· 2 days agoThe drop comes as Moderna awaits important developments involving its experimental cancer treatment, a new respiratory vaccine, and a possible avian flu...
Should You Buy This Stock After a Regulatory Setback? | The Motley Fool
The Motley Fool· 5 days agoThe past two-and-a-half years have been rough for Moderna (MRNA 1.58%). The company is developing...